HealZen Inks Global DAC Partnership, Second TPD Deal Following J&J Alliance
Hangzhou HealZen Therapeutics Co., Ltd. announced a global partnership with an undisclosed American biotechnology company...
Daiichi Sankyo Secures Breakthrough Therapy Designation for CDH6‑Targeted ADC Raludotatug Deruxtecan in Ovarian Cancer
Daiichi Sankyo (TYO: 4568) announced that Raludotatug Deruxtecan (R‑DXd, DS‑6000a), a first‑in‑class CDH6‑targeted antibody‑drug conjugate (ADC),...
Novo Nordisk Expands Aspect Biosystems Partnership for Diabetes Cell Therapy
Novo Nordisk (NYSE: NVO) and Canadian biotechnology firm Aspect Biosystems announced a new phase in their...
Sisram Medical Partners with Fosun Pharma Subsidiary on Local Production Base
Sisram Medical Ltd (HKG: 1696), an Israel‑based beauty and wellness group and part of Fosun...
BD and Ypsomed Develop Neopak XtraFlow 5.5mL Prefilled Syringe for YpsoMate Auto‑Injector
Becton, Dickinson and Co. (BD) and Swiss injection system developer Ypsomed announced an expanded collaboration...
Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services
Syngene International, a global contract research, development, and manufacturing organization (CRDMO), announced the extension of...
Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that SHR‑7877 has received National Medical Products...
PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline
PrimeGenX Therapeutics Co., Ltd., a Beijing‑based immune‑inflammatory disease specialist founded in 2016, has filed for...
J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth
Johnson & Johnson (J&J, NYSE: JNJ) reported fourth‑quarter revenue of $24.6 billion, up 9.1% year‑on‑year (YOY), bringing...
AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis
AbbVie Inc. (NYSE: ABBV) announced that China’s National Medical Products Administration (NMPA) has approved Risankizumab (SKYRIZI)...
Bio‑Sincerity Pharma‑Tech Secures Greater China Priority Rights for Delim’s Semaglutide and Tirzepatide Portfolio
Hangzhou Bio‑Sincerity Pharma‑Tech Co., Ltd. (SHE: 301096) announced a strategic cooperation agreement with Delim Cosmetics...
TaiGen and Joincare Partner on TG‑4318 DPP1 Inhibitor for Bronchiectasis in Greater China
TaiGen Biotechnology and Joincare Pharmaceutical Group (SHA: 600380) announced a licensing agreement for the collaborative...
China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy
China Isotope & Radiation Corporation (HKG: 1763) announced it has officially entered into a commercial...
Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline
Matwings Technology, a pioneer in AI‑driven protein engineering, announced a strategic biopharmaceutical pipeline collaboration with...
AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal
Tianjin AmCellGene Co., Ltd. has granted Hong Kong‑based Advanced Regeneration exclusive regional rights to commercialize...
Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P‑CAB from Sinorda
Huadong Medicine Co., Ltd. (SHE: 000963), a leading China‑based pharmaceutical group, announced an exclusive commercialization...
Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer
AstraZeneca plc (AZ, NASDAQ: AZN) and Daiichi Sankyo Company, Limited (TYO: 4568) announced that Enhertu (trastuzumab deruxtecan)...
AstraZeneca’s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication
AstraZeneca (AZ, NASDAQ: AZN) announced that Imfinzi (durvalumab) has been officially approved in China for use...
HeartCare Medical’s Intracranial Drug‑Eluting Stent Gets NMPA Filing Nod
Shanghai HeartCare Medical Technology Co., Ltd (HKG: 6609) announced that China’s National Medical Products Administration...
Abbott’s TactiFlex Duo Wins CE Mark for Atrial Fibrillation Treatment in Europe
Abbott (NYSE: ABT) announced it has received CE Mark approval in Europe for the TactiFlex Duo...